Peyman Hosseinchi, PhD

Senior Associate

---

Peyman Hosseinchi joined the T1D Fund in mid-February 2026. He brings experience in biotech company creation, investing in private and public biotech’s, and early-stage therapeutic strategy.

Prior to joining the Fund, Peyman was at Raven Venture (company creation arm of RA Capital), where he ideated new therapeutic concepts and led corporate development and strategy in portfolio companies. While at Raven, Peyman was a founding member of multiple NewCos across various therapeutic areas, including Stylus Medicine.

Earlier, Peyman was an Associate in RA Capital Management’s TechAtlas division, where he focused on investing in emerging therapeutic companies and providing strategic guidance for RA’s portfolio companies.

Peyman holds a PhD in Molecular Engineering from the University of Chicago and a dual B.S. in Mechanical & Aerospace Engineering from Sharif University of Technology in Tehran.